AU2018233109B2 - Pharmaceutical combination comprising ponesimod - Google Patents

Pharmaceutical combination comprising ponesimod Download PDF

Info

Publication number
AU2018233109B2
AU2018233109B2 AU2018233109A AU2018233109A AU2018233109B2 AU 2018233109 B2 AU2018233109 B2 AU 2018233109B2 AU 2018233109 A AU2018233109 A AU 2018233109A AU 2018233109 A AU2018233109 A AU 2018233109A AU 2018233109 B2 AU2018233109 B2 AU 2018233109B2
Authority
AU
Australia
Prior art keywords
ponesimod
teriflunomide
active ingredient
treatment
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018233109A
Other languages
English (en)
Other versions
AU2018233109A1 (en
Inventor
Martine Clozel
Laetitia POUZOL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Juvise Pharmaceuticals SAS
Original Assignee
Laboratoires Juvise Pharmaceuticals SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Juvise Pharmaceuticals SAS filed Critical Laboratoires Juvise Pharmaceuticals SAS
Publication of AU2018233109A1 publication Critical patent/AU2018233109A1/en
Application granted granted Critical
Publication of AU2018233109B2 publication Critical patent/AU2018233109B2/en
Priority to AU2023274118A priority Critical patent/AU2023274118B2/en
Assigned to LABORATOIRES JUVISE PHARMACEUTICALS reassignment LABORATOIRES JUVISE PHARMACEUTICALS Request for Assignment Assignors: ACTELION PHARMACEUTICALS LTD
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
AU2018233109A 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod Active AU2018233109B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023274118A AU2023274118B2 (en) 2017-03-14 2023-11-29 Pharmaceutical combination comprising ponesimod

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/055994 2017-03-14
EP2017055994 2017-03-14
PCT/EP2018/056185 WO2018167030A1 (en) 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023274118A Division AU2023274118B2 (en) 2017-03-14 2023-11-29 Pharmaceutical combination comprising ponesimod

Publications (2)

Publication Number Publication Date
AU2018233109A1 AU2018233109A1 (en) 2019-08-22
AU2018233109B2 true AU2018233109B2 (en) 2023-09-28

Family

ID=61655772

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018233109A Active AU2018233109B2 (en) 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod
AU2023274118A Active AU2023274118B2 (en) 2017-03-14 2023-11-29 Pharmaceutical combination comprising ponesimod

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023274118A Active AU2023274118B2 (en) 2017-03-14 2023-11-29 Pharmaceutical combination comprising ponesimod

Country Status (24)

Country Link
US (3) US11723896B2 (enExample)
EP (1) EP3595657A1 (enExample)
JP (3) JP7281406B2 (enExample)
KR (1) KR102574562B1 (enExample)
CN (1) CN110381942B (enExample)
AU (2) AU2018233109B2 (enExample)
BR (1) BR112019018894A2 (enExample)
CA (1) CA3056301C (enExample)
CL (1) CL2019002525A1 (enExample)
CO (1) CO2019008510A2 (enExample)
CR (1) CR20190464A (enExample)
DO (1) DOP2019000257A (enExample)
EA (1) EA201992117A1 (enExample)
EC (1) ECSP19073317A (enExample)
IL (1) IL269239B2 (enExample)
JO (1) JOP20190207A1 (enExample)
MA (1) MA49822A (enExample)
MX (1) MX390941B (enExample)
NI (1) NI201900092A (enExample)
PE (1) PE20191489A1 (enExample)
PH (1) PH12019502110A1 (enExample)
SG (1) SG11201907308UA (enExample)
UA (1) UA125756C2 (enExample)
WO (1) WO2018167030A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044741A1 (en) * 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
WO2016091996A1 (en) * 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (nl) 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
EP1257270B1 (en) * 2000-02-15 2005-04-13 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
DK1381356T3 (da) 2001-04-05 2008-09-22 Aventis Pharma Inc Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose
US6894184B2 (en) 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
BRPI0416752B8 (pt) 2003-11-21 2021-05-25 Actelion Pharmaceuticals Ltd composição farmacêutica, uso de um ou mais compostos, e, compostos
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
DK2094676T3 (da) 2006-11-23 2013-06-10 Actelion Pharmaceuticals Ltd Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
CA2716448A1 (en) 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
CA2772275A1 (en) 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
AR082436A1 (es) 2010-08-02 2012-12-05 Sanofi Aventis Us Llc Uso de teriflunomida para tratar la esclerosis multiple
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
HUE050733T2 (hu) 2012-08-17 2021-01-28 Actelion Pharmaceuticals Ltd Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék
WO2016079687A1 (en) 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
JP2018517736A (ja) 2015-06-18 2018-07-05 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド 炎症性疾患又は病態を治療する組成物及び方法
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044741A1 (en) * 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
WO2016091996A1 (en) * 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist

Also Published As

Publication number Publication date
CN110381942B (zh) 2022-12-27
US11723896B2 (en) 2023-08-15
CA3056301A1 (en) 2018-09-20
IL269239B1 (en) 2023-03-01
US20260108501A1 (en) 2026-04-23
JP2020510045A (ja) 2020-04-02
CL2019002525A1 (es) 2020-02-07
DOP2019000257A (es) 2020-09-15
KR20190122716A (ko) 2019-10-30
ECSP19073317A (es) 2019-11-30
SG11201907308UA (en) 2019-09-27
NI201900092A (es) 2020-03-11
JP7281406B2 (ja) 2023-05-25
US20240139161A1 (en) 2024-05-02
US12527772B2 (en) 2026-01-20
CN110381942A (zh) 2019-10-25
JP2024096962A (ja) 2024-07-17
AU2018233109A1 (en) 2019-08-22
CO2019008510A2 (es) 2019-10-21
EA201992117A1 (ru) 2020-02-17
EP3595657A1 (en) 2020-01-22
PE20191489A1 (es) 2019-10-21
US20200069655A1 (en) 2020-03-05
MA49822A (fr) 2020-06-17
JP2023030091A (ja) 2023-03-07
BR112019018894A2 (pt) 2020-04-14
MX390941B (es) 2025-03-21
UA125756C2 (uk) 2022-06-01
IL269239B2 (en) 2023-07-01
AU2023274118A1 (en) 2023-12-21
MX2019010874A (es) 2019-12-11
AU2023274118B2 (en) 2024-12-12
WO2018167030A1 (en) 2018-09-20
JOP20190207A1 (ar) 2019-09-10
KR102574562B1 (ko) 2023-09-04
PH12019502110A1 (en) 2020-03-16
CA3056301C (en) 2024-10-01
CR20190464A (es) 2019-11-26
IL269239A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
AU2023274118B2 (en) Pharmaceutical combination comprising ponesimod
US12409167B2 (en) Pharmaceutical combination comprising a selective S1P1 receptor agonist
EA041630B1 (ru) Фармацевтическая комбинация, содержащая понесимод
WO2015065628A2 (en) Laquinimod combination therapy for treatment of multiple sclerosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: LABORATOIRES JUVISE PHARMACEUTICALS

Free format text: FORMER OWNER(S): ACTELION PHARMACEUTICALS LTD